Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot...

Descripción completa

Detalles Bibliográficos
Autores principales: Diotti, Roberta Antonia, Capra, Ruggero, Moiola, Lucia, Caputo, Valeria, De Rossi, Nicola, Sangalli, Francesca, Martinelli, Vittorio, Burioni, Roberto, Clementi, Massimo, Mancini, Nicasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885083/
https://www.ncbi.nlm.nih.gov/pubmed/27164128
http://dx.doi.org/10.3390/v8050128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885083/
https://www.ncbi.nlm.nih.gov/pubmed/27164128
http://dx.doi.org/10.3390/v8050128

Ejemplares similares